SAN DIEGO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Amydis Inc., a privately held clinical-stage company pioneering a platform of diagnostic…
TORONTO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) has…
China CDE accepts Investigational New Drug (IND) application for lead gene therapy product candidate, FT-001, for the treatment of a…
Four patents issued expanding claims related to delivery of nVNS and other therapies using mobile devicesROCKAWAY, N.J., Sept. 21, 2022…
The study evaluating a long-acting glatiramer acetate injection, GA Depot 40 mg once every four weeks, met the primary endpoint,…
STS101 demonstrated a favorable safety and tolerability profile, consistent with clinical experience to dateOver 8,000 migraine attacks treated with more…
ROCKAWAY, N.J., Sept. 20, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic medicine company, today…
Promising efficacy and safety profiles were observed in prior Phase II studies in acute ischemic stroke patients treated with recanalization…
– Scientific collaborators at Stanford University will present data on an imaging and treatment regimen demonstrating the microglial targeting of…
-- Dr. Cudkowicz is a pioneer in the study and treatment of people with Amyotrophic Lateral Sclerosis (ALS) and other…